Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy

Journal of the American College of Cardiology

Volumn 35, Issue 7, 2000, Pages 1867-1873

  Li, Sheng Ting ^a   Tack, Cees J ^b   Fananapazir, Lameh ^c   Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPAMINE; ADRENERGIC RECEPTOR; AMMONIA; CATECHOLAMINE; FLUORINE 18; NITROGEN 13; NORADRENALIN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CELL MEMBRANE TRANSPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HEART INNERVATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; NEUROTRANSMITTER UPTAKE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ATTENUATION; RADIOACTIVITY; SYMPATHETIC INNERVATION; SYMPATHETIC NERVE;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY CIRCULATION; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HEART; HUMANS; MALE; SYMPATHETIC NERVOUS SYSTEM; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034117539     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00626-4     Document Type: Article

References (44)

1. Wigle E.D., Rakowski H., Kimball B.P., Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 92:1995;1680-1692.
2. Fananapazir L., Chang A.C., Epstein S.E., McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. 86:1992;730-740.
3. Maron B.J., Bonow R.O., Cannon R.O., Leon M.B., Epstein S.E. Hypertrophic cardiomyopathy interrelation of clinical manifestation, pathophysiology, and therapy . N Engl J Med. 316:1987;780-789.
4. Maron B.J. Hypertrophic cardiomyopathy. Lancet. 350:1997;127-133.
5. Jeschke B., Uhl K., Weist B., et al. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes. Hum Genet. 102:1998;299-304.
6. Thierfelder L., Watkins H., MacRae C., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy a disease of the sarcomere . Cell. 77:1994;701-712.
7. Bonne G., Carrier L., Bercovici J., et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet. 11:1995;438-440.
8. Poetter K., Jiang H., Hassanzadeh S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 13:1996;63-69.
9. Kimura A., Harada H., Park J.E., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 16:1997;379-382.
10. Lankford E.B., Epstein N.D., Fananapazir L., Sweeney H.L. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest. 95:1995;1409-1414.
11. Coviello D.A., Maron B.J., Spirito P., et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol. 29:1997;635-640.
12. Wigle E.D., Sasson Z., Henderson M.A. Hypertrophic cardiomyopathy the importance of the site and the extent of hypertrophy. A review . Prog Cardiovasc Dis. 48:1985;1-83.
13. Cohen L.S., Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 35:1967;847-851.
14. Korner P.I., Bobik A., Oddie C., Friberg P. Sympathoadrenal system is critical for structural changes in genetic hypertension. Hypertension. 22:1993;243-252.
15. Genovese A., Chiariello M., Bozzaotre M., Latte S., De Alfieri W., Condorelli M. Adrenergic activity as a modulating factor in the genesis of myocardial hypertrophy in the rat. Exp Mol Pathol. 41:1984;390-396.
16. Zierhut W., Zimmer H.G. Significance of myocardial α- and β-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res. 65:1989;1417-1425.
17. Kolbeck-Ruhmkorff C., Zimmer H.G. Proto-oncogene expression in the isolated working rat heart combination of pressure and volume overload with norepinephrine . J Mol Cell Cardiol. 27:1995;501-511.
18. Brush J.E. Jr, Eisenhofer G., Garty M., et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 79:1989;836-844.
19. Goldstein D.S., Brush J.E. Jr, Eisenhofer G., Stull R., Esler M. In vivo measurement of neuronal uptake of norepinephrine in the human heart. Circulation. 78:1988;41-48.
20. Esler M.D., Wallin G., Dorward P.K., et al. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol. 260:1991;R817-R823.
21. Ungerer M., Hartmann F., Karoglan M., et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation. 97:1998;174-180.
22. Shimizu M., Sugihara N., Kita Y., et al. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J. 67:1992;155-160.
23. Schafers M., Dutka D., Rhodes C.G., et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res. 82:1998;57-62.
24. Eisenhofer G., Hovevey-Sion D., Kopin I.J., et al. Neuronal uptake and metabolism of 2- and 6-fluorodopamine false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues . J Pharmacol Exp Ther. 248:1989;419-427.
25. Goldstein D.S., Chang P.C., Eisenhofer G., et al. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation. 81:1990;1606-1621.
26. Goldstein D.S., Grossman E., Listwak S., Folio C.J. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension. 18:(Suppl III):1991;III-40-III-48.
27. 18F]-fluorodopamine initial findings in humans . J Am Coll Cardiol. 22:1993;1961-1971.
28. Goldstein D.S., Holmes C., Cannon R.O. III, Eisenhofer G., Kopin I.J. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med. 336:1997;696-702.
29. 18F]-Fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function - studies in normal humans. Clin Auton Res. 7:1997;17-29.
30. Chiueh C.C., Zukowska-Grojec Z., Kirk K.L., Kopin I.J. 6-Fluorocatecholamines as false adrenergic neurotransmitters. J Pharmacol Exp Ther. 225:1983;529-533.
31. 18F-6-fluorodopamine effects of chemical sympathectomy by 6-hydroxydopamine . J Hypertens. 9:1991;417-423.
32. 18F]6-fluorodopamine as a measure of cardiac sympathetic activity in humans. Heart. 75:1996;29-34.
33. 15O]water techniques. Circulation. 93:1996;2000-2006.
34. Grover-McKay M., Schwaiger M., Krivokapich J., Perloff J.K., Phelps M.E., Schelbert H.R. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 13:1989;317-324.
35. Bartlett M.L., Bacharach S.L., Voipio-Pulkki L.M., Dilsizian V. Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med. 36:1995;188-195.
36. 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 119:1990;1329-1337.
37. Ishiwata S., Maruno H., Senda M., Toyama H., Nishiyama S., Seki A. Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy - a study with carbon-11 acetate and positron emission tomography. Jpn Circ J. 61:1997;201-210.
38. Tadamura E., Tamaki N., Matsumori A., et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med. 37:1996;572-577.
39. Schwartzkopff B., Mundhenke M., Strauer B.E. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve a possible cause for myocardial ischemia . J Am Coll Cardiol. 31:1998;1089-1096.
40. Camici P., Chiriatti G., Lorenzoni R., et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy a study with nitrogen-13 ammonia and positron emission tomography . J Am Coll Cardiol. 17:1991;879-886.
41. Gropler R.J., Siegel B.A., Geltman E.M. Myocardial uptake of carbon-11-acetate as an indirect estimate of regional myocardial blood flow. J Nucl Med. 32:1991;245-251.
42. Nienaber C.A., Gambhir S.S., Mody F.V., et al. Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. Circulation. 87:1993;1580-1590.
43. Choudhury L., Rosen S.D., Patel D., Nihoyannopoulos P., Camici P.G. Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography. Eur Heart J. 18:1997;108-116.
44. Perrone-Filardi P., Bachrarach S.L., Dilsizian V., Panza J.A., Maurea S., Bonow R.O. Regional systolic function, myocardial blood flow and glucose uptake at rest in hypertrophic cardiomyopathy. Am J Cardiol. 72:1993;199-204.